Patents Assigned to N.V. Organon
  • Patent number: 8563694
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: October 22, 2013
    Assignees: Medarex, Inc., N.V.Organon
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Publication number: 20130225559
    Abstract: The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush.
    Type: Application
    Filed: April 5, 2013
    Publication date: August 29, 2013
    Applicant: N.V. Organon
    Inventors: Bernardus Wijnand Mathys Marie Peeters, Anton Egbert Peter Adang
  • Publication number: 20130023566
    Abstract: The invention relates to 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives having the general Formula (I) wherein R1 represents the group CONR2R3 which is present at one of the positions 5-, 6- or 7- on the 1,2-benzisoxazole ring; R2 and R3 are independently H or (C1-4)alkyl; and R4 is cyclopropyl, 2-pyridyl or phenyl, optionally substituted with one or more halogens; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.
    Type: Application
    Filed: July 6, 2010
    Publication date: January 24, 2013
    Applicant: N.V. Organon
    Inventor: Simon James Anthony Grove
  • Publication number: 20120309966
    Abstract: The present invention provides 8-methyl-1-phenyl-imidazo[1,5-a]pyrazine deriva-tives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.
    Type: Application
    Filed: February 3, 2011
    Publication date: December 6, 2012
    Applicant: N.V. ORGANON
    Inventors: Adrianus Petrus Antonius de Man, Johannes Bernardus Maria Rewinkel, Christian Gerardus Johannes Maria Jans, Hans Cornelis Andreas Raajimakers, Jacobus Cornelis Henricus Maria Wijkmans
  • Publication number: 20120302552
    Abstract: The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush.
    Type: Application
    Filed: August 9, 2012
    Publication date: November 29, 2012
    Applicant: N. V. Organon
    Inventors: Bernardus Wijnand Mathys Marie Peeters, Anton Egbert Peter Adang
  • Publication number: 20120245175
    Abstract: The present invention relates to compounds of general Formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used in the treatment of immune, autoimmune, inflammatory diseases, cardiovascular diseases, infectious diseases, bone resorption disorders, neurodegenerative diseases or proliferative diseases.
    Type: Application
    Filed: December 13, 2010
    Publication date: September 27, 2012
    Applicant: N.V. ORGANON
    Inventors: Tjeerd Andries Barf, Arthur Oubrie, Carsten Schultz-Fademrecht, Eduard Willem Zwart, Niels Hoogenboom, Sander Martijn De Wilde, Allard Kaptein
  • Publication number: 20120238574
    Abstract: The present invention relates to (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives having the general formula (I) to pharmaceutical compositions comprising the same and to the use of these (1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl)phenyl derivatives in the treatment of atherosclerosis.
    Type: Application
    Filed: October 26, 2010
    Publication date: September 20, 2012
    Applicant: N.V. ORGANON
    Inventors: Andrew John Cooke, Emma Louise Carswell, David Jonathan Bennett
  • Publication number: 20120202996
    Abstract: The present invention relates to tetrahydroquinoline derivatives having general formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is formyl, (1-6C)alkylcarbonyl or (1-6C)alkylsulfonyl; R2 and R3 are H or (1-4C)alkyl; R4 is phenyl; R5 is (1-4C)alkyl; Y—X is C(O)—O, S(O)2-O, NHC(O)—O, NHC(S)—O, OC(O)—O, bond-O, C(O)—NH, S(O)2-NH, NHC(O)—NH, NHC(S)—NH, OC(O)—NH, bond-NH, NH—C(O), O—C(O), NH—S(O)2, or O—S(O)2 or Y—X is a bond; R6 is H, trifluoromethyl, (1-6C)alkyl, 1- or 2-adamantyl(1-4C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-9C)heteroaryl, (3-6C)cycloalkyl, (2-6C)heterocycloalkyl, (1-4C)alkylthio(1-4C)alkyl, (6-10C)aryl(1-4C)alkyl, (3-9C)heteroaryl(1-4C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl, (2-6C)heterocycloalkyl(1-4C)alkyl, R8,R9-aminocarbonyl(1-4C)alkyl, R8,R9-amino(1-4C)alkyl, R8-oxycarbonyl(1-4C)alkyl, R8-oxy(1-4C)alkyl, R8-carbonyl(1-4C)alkyl or (6-10C)aryl; R7 is H, (1-4C)alkyl, (1-4C)alkoxy, halogen, trifluoromethyl, cyano, nitro, hydroxyl; and R8 and/or R9 is H, (1-4C)alkyl, (2-4C
    Type: Application
    Filed: October 7, 2011
    Publication date: August 9, 2012
    Applicant: N.V. Organon
    Inventors: Nicole Corine Renée Van Straten, Rudolf Gijsbertus Van Someren, Jurgen Schulz
  • Publication number: 20120183565
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: July 26, 2010
    Publication date: July 19, 2012
    Applicants: N.V. ORGANON, MEDAREX, INC.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Publication number: 20120107870
    Abstract: The present invention relates to a process for the amidation of C-terminal esters or acids of peptide substrates in solution-phase synthesis of peptides, comprising amidating one or more peptide substrates comprising C-terminal esters or acids using the protease subtilisin in any suitable form in the presence of an ammonium salt derived from an acid having a pKa above 0. This process is useful in the production of protected or unprotected peptides.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 3, 2012
    Applicant: N.V. Organon
    Inventors: Ivo Franci Eggen, Carmen Gabriela Boeriu
  • Publication number: 20120095002
    Abstract: The present invention relates to isoxazole-5-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-5-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and chronic neuropathic pain, acute and chronic inflammatory pain, respiratory diseases, and lower urinary tract disorders.
    Type: Application
    Filed: February 2, 2010
    Publication date: April 19, 2012
    Applicant: N.V. Organon
    Inventors: Paul David Ratcliffe, Ronald Palin
  • Patent number: 8124372
    Abstract: The present invention relates to a process for the amidation of C-terminal esters or acids of peptide substrates in solution-phase synthesis of peptides, comprising amidating one or more peptide substrates comprising C-terminal esters or acids using the protease subtilisin in any suitable form in the presence of an ammonium salt derived from an acid having a pKa above 0. This process is useful in the production of protected or unprotected peptides.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: February 28, 2012
    Assignee: N.V. Organon
    Inventors: Ivo Franci Eggen, Carmen Gabriela Boeriu
  • Patent number: 8124647
    Abstract: This invention provides non-steroidal compounds with affinity for the androgen receptor and utility for androgen-receptor related treatments, having a structure according to the formula or a salt or hydrate form thereof.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: February 28, 2012
    Assignee: N.V. Organon
    Inventors: Pedro Harold Han Hermkens, Herman Thijs Stock, Jaap Van Der Louw, Neeltje Miranda Teerhuis, Johannes Petrus Maria Lommerse
  • Publication number: 20120039843
    Abstract: The present invention relates to conjugates of a polypeptide and an oligosaccharide, wherein the polypeptide is conjugated to at least one oligosaccharide-spacer residue, the oligosaccharide being a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units and per se having affinity to antithrombin III and the spacer being a bond or an essentially pharmacologically inactive flexible linking residue, or a pharmaceutically acceptable salt thereof. The conjugates of the invention have improved pharmacokinetic properties when compared to the original polypeptides (i.e. the corresponding non-conjugated polypeptides per se).
    Type: Application
    Filed: September 8, 2011
    Publication date: February 16, 2012
    Applicant: N.V. Organon
    Inventors: Ebo Sybren Bos, Martin De Kort, Meertinus Jan Smit, Constant Adriaan Anton Van Boeckel
  • Patent number: 8106007
    Abstract: The present invention relates to conjugates of a polypeptide and an oligosaccharide, wherein the polypeptide is conjugated to at least one oligosaccharide-spacer residue, the oligosaccharide being a synthetic sulfated oligosaccharide comprising 4-18 monosaccharide units and per se having affinity to antithrombin III and the spacer being a bond or an essentially pharmacologically inactive flexible linking residue, or a pharmaceutically acceptable salt thereof. The conjugates of the invention have improved pharmacokinetic properties when compared to the original polypeptides (i.e. the corresponding non-conjugated polypeptides per se).
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: January 31, 2012
    Assignee: N.V. Organon
    Inventors: Ebo Sijbren Bos, Martin De Kort, Meertinus Jan Smit, Constant Adriaan Anton Van Boeckel
  • Patent number: 8071589
    Abstract: The invention relates to benzoindazole derivatives according to general Formula I or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: December 6, 2011
    Assignee: N. V. Organon
    Inventors: Cornelis Marius Timmers, Hubert Jan Jozef Loozen
  • Patent number: 8071587
    Abstract: The invention relates to imidazoiso[5,1-a]quinoline and 5,6-dihydro-imidazoiso[5,1-a]quinoline derivatives according to general Formula I or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: December 6, 2011
    Assignee: N. V. Organon
    Inventors: Hubert Jan Jozef Loozen, Cornelius Marius Timmers
  • Patent number: 8063037
    Abstract: The present invention provides new progesterone receptor modulators which are dibenzo[b,f]pyrido[1,2-d]oxazepine-2-amines or dibenzo[b,f]prido[1,2-d]thiazepine-2-amines, and uses thereof.
    Type: Grant
    Filed: May 6, 2008
    Date of Patent: November 22, 2011
    Assignee: N. V. Organon
    Inventors: Johannes Bernardus Maria Rewinkel, Brigitte Johanna Bernita Folmer, Maria Lourdes Ollero, Hemen Ibrahim
  • Patent number: 8063102
    Abstract: The present invention relates to novel tetrahydronaphthalen-2-ol derivatives, to pharmaceutical compositions comprising these compounds and to their use in therapy, in particular to their use for the manufacture of a medicament for the prevention or treatment of lower urinary tract symptoms, benign prostate hyperplasia, prostate cancer, hot flushes, anxiety, depression, breast cancer, medullary thyroid carcinoma, ovarian cancer, inflammatory bowel disease, arthritis, endometriosis, and colon cancer.
    Type: Grant
    Filed: March 11, 2010
    Date of Patent: November 22, 2011
    Assignee: N.V. Organon
    Inventors: Herman Thijs Stock, Neeltje Miranda Teerhuis, Gerrit Herman Veeneman
  • Patent number: 8058436
    Abstract: The invention provides a method for the preparation of enantiomerically pure mirtazapine, said method comprising a step of ring closure of a compound of formula (II) wherein X is a leaving group, said step comprising treatment with an acid, whereby mirlazapine with enantiomeric excess is formed by the ring closure of the compound of formula (II) with enantiomeric excess by treatment with a suitable acid in the absence of a solvent or a suitable combination of an acid and an organic solvent.
    Type: Grant
    Filed: July 5, 2004
    Date of Patent: November 15, 2011
    Assignee: N.V. Organon
    Inventors: Johannes Hubertus Wieringa, Adrianus Antonius Martinus Van De Ven, Gerardus Johannes Kemperman